Cyclophosphamide trials for Anatomic Stage III Breast Cancer AJCC v8

All Cyclophosphamide trials · All Anatomic Stage III Breast Cancer AJCC v8 trials

Phase breakdown

Recruiting trials studying Cyclophosphamide for Anatomic Stage III Breast Cancer AJCC v8

• Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
  NCT06058377 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 554 locations
• Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
  NCT06042569 · Phase: Phase 2 · Ages: 65 Years and older · Sex: All (male and female) · 3 locations
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
  NCT05269381 · Phase: Phase 1, Phase 2 · Ages: 16 Years and older · Sex: All (male and female) · 2 locations

Common questions

How many trials study Cyclophosphamide for Anatomic Stage III Breast Cancer AJCC v8?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.